Predictive probability of success and the assessment of futility in large outcomes trials

被引:9
作者
Trzaskoma, Benjamin [1 ]
Sashegyi, Andreas [1 ]
机构
[1] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
关键词
binary data; futility rules; overdispersion; predictive probability; prior distribution;
D O I
10.1080/10543400601001485
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We consider a class of futility rules based on a Bayesian approach for computing the predictive probability of success for large clinical trials, given a certain amount of observed data. This paper focuses on outcomes trials in particular, thus we are concerned with binary response variables. The proposed method determines the likelihood of observing a statistically significant treatment effect at the end of a study, conditional on the data observed at an interim time point and assuming that event rates governing future observations follow beta distributions. In particular, the prior distributions for the event rates of interest are updated based on the observed data at an interim time point, such that means and variances are intuitive functions of the data. Computational aspects will be discussed for the case in which event counts are functions of sample size and event rates only, and for situations in which they are functions of sample size, event rates, and exposure duration. We will discuss appropriate thresholds for declaring futility based on this approach, and the potential impact of overdispersion, a common phenomenon particularly in global outcomes trials.
引用
收藏
页码:45 / 63
页数:19
相关论文
共 21 条
  • [1] Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death
    Abraham, E
    Laterre, P
    Garg, R
    Levy, H
    Talwar, D
    Trzaskoma, BL
    Francois, B
    Guy, JS
    Bruckmann, M
    Rea-Neto, A
    Rossaint, R
    Perrotin, D
    Sablotzki, A
    Arkins, N
    Utterback, BG
    Macias, WL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (13) : 1332 - 1341
  • [2] [Anonymous], 1997, Boostrap methods and their application
  • [3] Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women
    Barrett-Connor, Elizabeth
    Mosca, Lori
    Collins, Peter
    Geiger, Mary Jane
    Grady, Deborah
    Kornitzer, Marcel
    McNabb, Michelle A.
    Wenger, Nanette K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (02) : 125 - 137
  • [4] Efficacy and safety of recombinant human activated protein C for severe sepsis.
    Bernard, GR
    Vincent, JL
    Laterre, P
    LaRosa, SP
    Dhainaut, JF
    Lopez-Rodriguez, A
    Steingrub, JS
    Garber, GE
    Helterbrand, JD
    Ely, EW
    Fisher, CJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) : 699 - 709
  • [5] EXPLAINING THE GIBBS SAMPLER
    CASELLA, G
    GEORGE, EI
    [J]. AMERICAN STATISTICIAN, 1992, 46 (03) : 167 - 174
  • [6] EARLY DECISION IN CLINICAL-TRIALS WHEN THE TREATMENT DIFFERENCES ARE SMALL - EXPERIENCE OF A CONTROLLED TRIAL IN HEAD TRAUMA
    CHOI, SC
    SMITH, PJ
    BECKER, DP
    [J]. CONTROLLED CLINICAL TRIALS, 1985, 6 (04): : 280 - 288
  • [7] A comment on futility monitoring
    Freidlin, B
    Kom, EL
    [J]. CONTROLLED CLINICAL TRIALS, 2002, 23 (04): : 355 - 366
  • [8] Gelman A, 2013, BAYESIAN DATA ANAL, DOI DOI 10.1201/9780429258411
  • [9] Is volume related to outcome in health care? A systematic review and methodologic critique of the literature
    Halm, EA
    Lee, C
    Chassin, MR
    [J]. ANNALS OF INTERNAL MEDICINE, 2002, 137 (06) : 511 - 520
  • [10] AN AID TO DATA MONITORING IN LONG-TERM CLINICAL-TRIALS
    HALPERIN, M
    LAN, KKG
    WARE, JH
    JOHNSON, NJ
    DEMETS, DL
    [J]. CONTROLLED CLINICAL TRIALS, 1982, 3 (04): : 311 - 323